Analyzing Athenex (NASDAQ:ATNX) and ImmunoPrecise Antibodies (NASDAQ:IPA)
Analyzing Athenex (NASDAQ:ATNX) and ImmunoPrecise Antibodies (NASDAQ:IPA)
Athenex (NASDAQ:ATNX – Get Rating) and ImmunoPrecise Antibodies (NASDAQ:IPA – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.
Earnings and Valuation
This table compares Athenex and ImmunoPrecise Antibodies' gross revenue, earnings per share and valuation.
Get Athenex alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Athenex | $120.18 million | 1.11 | -$199.77 million | ($1.72) | -0.64 |
ImmunoPrecise Antibodies | $15.32 million | 6.89 | -$13.32 million | ($0.68) | -6.25 |
ImmunoPrecise Antibodies has lower revenue, but higher earnings than Athenex. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Athenex, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Athenex has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.Profitability
This table compares Athenex and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Athenex | -160.39% | -258.81% | -43.21% |
ImmunoPrecise Antibodies | -86.21% | -29.03% | -24.23% |
Insider and Institutional Ownership
40.9% of Athenex shares are held by institutional investors. Comparatively, 6.6% of ImmunoPrecise Antibodies shares are held by institutional investors. 12.0% of Athenex shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Athenex and ImmunoPrecise Antibodies, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Athenex | 0 | 1 | 1 | 0 | 2.50 |
ImmunoPrecise Antibodies | 0 | 0 | 1 | 0 | 3.00 |
Athenex presently has a consensus price target of $4.00, suggesting a potential upside of 263.64%. ImmunoPrecise Antibodies has a consensus price target of $12.00, suggesting a potential upside of 182.35%. Given Athenex's higher probable upside, research analysts plainly believe Athenex is more favorable than ImmunoPrecise Antibodies.
Summary
ImmunoPrecise Antibodies beats Athenex on 7 of the 13 factors compared between the two stocks.
About Athenex
(Get Rating)
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
About ImmunoPrecise Antibodies
(Get Rating)
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.
Athenex(納斯達克:ATNX-GET評級)和免疫精抗體(納斯達克:IPA-GET評級)都是小盤醫療公司,但哪隻股票更好?我們將根據這兩家公司的股息實力、分析師建議、機構所有權、風險、估值、收益和盈利能力對它們進行比較。
收益和估值
下表比較了Athenex和免疫精選抗體公司的總收入、每股收益和估值。
到達Athenex警報:總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 本益比 | |
Athenex | 1.2018億美元 | 1.11 | -1.997億美元 | (1.72美元) | -0.64 |
免疫精確化抗體 | 1,532萬美元 | 6.89 | -1332萬美元 | (0.68美元) | -6.25 |
免疫精準抗體的收入低於Athenex,但收益高於Athenex。免疫精選抗體的本益比低於Athenex,這表明它目前是兩只股票中更負擔得起的一隻。
風險與波動性
Athenex的貝塔係數為1.09,這意味著其股價的波動性比S標準普爾500指數高出9%。相比之下,免疫精準抗體的貝塔係數為0.57,這意味著其股價的波動性比S標準普爾500指數低43%。盈利能力
此表比較了Athenex和免疫精選抗體公司的淨利潤率、股本回報率和資產回報率。
淨利潤率 | 股本回報率 | 資產回報率 | |
Athenex | -160.39% | -258.81% | -43.21% |
免疫精確化抗體 | -86.21% | -29.03% | -24.23% |
內部人與機構持股
40.9%的Athenex股票由機構投資者持有。相比之下,免疫精抗體6.6%的股份由機構投資者持有。Athenex 12.0%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、對沖基金和捐贈基金相信,一家公司有望實現長期增長。
分析師評級
這是由MarketBeat提供的對Athenex和免疫精製抗體的最近評級和推薦的細目。
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
Athenex | 0 | 1 | 1 | 0 | 2.50 |
免疫精確化抗體 | 0 | 0 | 1 | 0 | 3.00 |
Athenex目前的共識目標價為4美元,暗示潛在上漲263.64%。免疫精製抗體的一致目標價為12.00美元,暗示潛在上漲182.35%。鑑於Athenex的上行可能性更高,研究分析師顯然認為Athenex比免疫精製抗體更有利。
摘要
免疫精準抗體在兩只股票之間的13個因素中有7個擊敗了Athenex。
關於Athenex
(獲取評級)
Athenex,Inc.是一家生物製藥公司,從事癌症治療藥物的發現、開發和商業化。它通過三個部分運作:腫瘤學創新平臺、全球供應鏈平臺和商業平臺。該公司的Orascovery候選產品包括口服紫杉醇和Enequidar,這是一種口服劑型,正處於轉移性乳腺癌的第三階段試驗,以及針對皮膚血管肉瘤、進展期胃癌和進展期實體惡性腫瘤的各種臨床研究。它還提供由替巴尼布林軟膏組成的Src Kinase候選產品,用於治療光化性角化病、皮膚癌和牛皮癬。此外,該公司正在開發KUR-501,這是一種用於治療復發難治性(R/R)高風險神經母細胞瘤的兒童的自體產品,處於I期臨床試驗;KUR-502,這是一種同種異體產品,處於治療成人R/R CD19陽性惡性腫瘤的第一階段臨床試驗,包括B細胞淋巴瘤、急性淋巴細胞白血病和慢性淋巴細胞白血病;以及KUR-503,這是一種處於晚期肝細胞癌臨床前開發的同種異體產品,以及TCRT-ESO-A2,一種自體T細胞受體(TCR)T細胞療法,處於實體腫瘤的第一階段臨床試驗。此外,它正在開發雙重吸收增強劑,以抑制胃腸道內的P-gp轉運體和細胞色素P450 3A酵素;並擁有一系列TCR,可識別多種腫瘤的P53、KRAS和EGFR基因的熱點突變。該公司前身為Kinex PharmPharmticals LLC,並於2015年8月更名為Athenex,Inc.Athenex,Inc.成立於2003年,總部設在紐約州布法羅。
關於免疫精確化抗體
(獲取評級)
免疫精抗體有限公司及其子公司在美國、加拿大、歐洲和國際上從事抗體生產和相關服務。該公司提供一系列抗體、酵素、酵素活性分析、關節炎動物產品、蛋白質、去亞胺蛋白、有機生長因數和雜交瘤產品用於研究目的。其服務包括定製抗原建模、設計和製造;B細胞分類、篩選和測序;定製、免疫和天然噬菌體展示生產和篩選;轉基因動物和多物種抗體發現;雙特異性、三特異性、VHH和VNAR(鯊魚)抗體制造;DNA克隆、蛋白質和抗體的下游加工;無標記生物感測器和抗體工程的抗體表徵;瞬時和穩定的細胞系生成;抗體優化和人性化;多重雜交瘤的生產、高通量篩選和克隆挑選;以及冷凍保存。該公司與Pierre Fabre S.A公司簽訂了抗體發現方面的研究合作協定,並與Elektrofi公司簽訂了研究合作協定,以探索高濃度新冠肺炎抗體雞尾酒配方多表位TATX-03。免疫精抗體有限公司成立於1983年,總部設在加拿大維多利亞。
接受Athenex日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Athenex和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧